|
W. David Henner, MD, PhD, serves as chief medical officer for Pathwork Diagnostics, where he will provide clinical and medical leadership for the company's clinical pipeline development, thought leader development, collaborations and clinical study design. Dr. Henner brings 25 years of significant scientific, clinical and industry experience to the company.
Prior to Pathwork, Dr. Henner was vice president of oncology at Novacea, Inc., a biopharmaceutical company, where he oversaw clinical development of the company's lead product candidates. Prior to that, he was vice president for clinical research and development at Telik, Inc., where he was responsible for conducting clinical trials of the company's oncology drug candidates.
Dr. Henner began his career on the faculty at Harvard Medical School and the Dana-Farber Cancer Institute from 1982 to 1988. From 1988 to 2001, Dr. Henner served as professor of medicine and pharmacology at Oregon Health & Science University, where he conducted research on anti-cancer drugs and practiced medical oncology.
Dr. Henner has published more than 70 papers and has been issued three U.S. patents for his discoveries. He received his MD and PhD in microbiology from the University of Pennsylvania. Dr. Henner completed his medical residency at the University of Chicago Hospital and his clinical fellowship in medical oncology at Harvard Medical School and the Dana-Farber Cancer Institute. He also holds an MBA from the University of Oregon. | 